title: Concurrent chemoradiotherapy for T4 patients with hypopharyngeal and laryngeal squamous cell carcinomas.
abstract: OBJECTIVE
  Concurrent chemoradiotherapy (CCR) was given for the previously untreated T4 hypopharyngeal and laryngeal squamous cell carcinoma patients and the response and survival rates were evaluated.
  
  
  METHODS
  A total of 23 patients, namely, 15 for hypopharynx and 8 for larynx were eligible. These patients were given cisplatin and 5-fluorouracil based chemotherapeutic regimens with conventional radiotherapy for a total dose of 66.6-70.2 Gy.
  
  
  RESULTS
  Ten out of the 15 hypopharyngeal carcinoma patients and 4 out of the 8 laryngeal carcinoma patients showed a complete response at the primary sites. The 5-year disease-specific survival rate was 59.4% in all the patients, 51.9% in the hypopharyngeal carcinoma patients, and 71.0% in the laryngeal patients. Seven out of the 12 resectable hypopharyngeal carcinoma patients and 4 out of 8 laryngeal carcinoma patients were able to do without total laryngectomy.
  
  
  CONCLUSIONS
  Based on these results, the survival rate in the hypopharyngeal and laryngeal T4 carcinoma patients treated by CCR seems to be satisfactory and the possibility of organ preservation for the advanced patients is indicated.
authors.affiliation: Department of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. gnishimu@yokohama-cu.ac.jp
authors.forename: Goshi
authors.initials: G
authors.lastname: Nishimura
authors.forename: Mamoru
authors.initials: M
authors.lastname: Tsukuda
authors.forename: Choichi
authors.initials: C
authors.lastname: Horiuchi
authors.forename: Kenichi
authors.initials: K
authors.lastname: Satake
authors.forename: Takafumi
authors.initials: T
authors.lastname: Yoshida
authors.forename: Junichi
authors.initials: J
authors.lastname: Nagao
authors.forename: Mariko
authors.initials: M
authors.lastname: Kawakami
authors.forename: Norio
authors.initials: N
authors.lastname: Kondo
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Arai
authors.forename: Takahide
authors.initials: T
authors.lastname: Taguchi
authors.forename: Hideki
authors.initials: H
authors.lastname: Matsuda
authors.forename: Yasukazu
authors.initials: Y
authors.lastname: Mikami
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D007825:Laryngectomy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D016879:Salvage Therapy
chemical_list: D002945:Cisplatin; D005472:Fluorouracil